Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
Classificação em ações #779
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Preço da ação
$17.82
Última sincronização: 2026-09-11
Valor de mercado
$32.43B
Variação (1 dia)
0.83%
Variação (1 ano)
-25.31%
País
JP
Negociar Daiichi Sankyo Company, Limited (4568)

Categoria

Receita da Daiichi Sankyo Company, Limited (4568)
Receita em Jun 2026 TTM: $14.75B
De acordo com os últimos relatórios financeiros da Daiichi Sankyo Company, Limited, a receita atual da empresa (TTM) é $14.75B. Em 2024, a empresa obteve uma receita de $10.58B um aumento em relação a a receita do ano 2023, que foi de $9.63B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Daiichi Sankyo Company, Limited de 2000 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $14.75B 17.20%
2025 $12.58B 18.91%
2024 $10.58B 9.90%
2023 $9.63B 12.20%
2022 $8.58B -1.25%
2021 $8.69B -4.84%
2020 $9.13B 9.03%
2019 $8.38B -7.32%
2018 $9.04B 5.39%
2017 $8.58B -2.19%
2016 $8.77B 14.38%
2015 $7.67B -29.30%
2014 $10.84B 2.39%
2013 $10.59B -6.41%
2012 $11.31B -3.05%
2011 $11.67B 14.54%
2010 $10.19B 19.06%
2009 $8.56B -3.04%
2008 $8.83B 12.02%
2007 $7.88B 0.11%
2006 $7.87B 43.33%
2005 $5.49B -4.11%
2004 $5.73B 18.80%
2003 $4.82B 16.37%
2002 $4.14B -4.69%
2001 $4.35B -24.27%
2000 $5.74B 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
$79.67B 440.19%
US
$97.93B 564.03%
US
$64.39B 336.59%
US
$77.52B 425.63%
CH
$66.40B 350.24%
US